Timothy P. Heffron

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Gillian S. Smelick, Timothy P. Heffron, Laura Chu et al. · Molecular Pharmaceutics · 2013 · 188 citations

Medicine, Oncology, Pharmacology +14

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 176 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Anthony A. Estrada, Xingrong Liu, Charles Baker‐Glenn et al. · Journal of Medicinal Chemistry · 2012 · 164 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Anthony A. Estrada, Bryan Chan, Charles Baker‐Glenn et al. · Journal of Medicinal Chemistry · 2013 · 126 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17